Luca Richeldi

58.5k total citations · 17 hit papers
356 papers, 18.3k citations indexed

About

Luca Richeldi is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Luca Richeldi has authored 356 papers receiving a total of 18.3k indexed citations (citations by other indexed papers that have themselves been cited), including 283 papers in Pulmonary and Respiratory Medicine, 108 papers in Physiology and 62 papers in Epidemiology. Recurrent topics in Luca Richeldi's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (247 papers), Sarcoidosis and Beryllium Toxicity Research (91 papers) and Medical Imaging and Pathology Studies (42 papers). Luca Richeldi is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (247 papers), Sarcoidosis and Beryllium Toxicity Research (91 papers) and Medical Imaging and Pathology Studies (42 papers). Luca Richeldi collaborates with scholars based in Italy, United Kingdom and United States. Luca Richeldi's co-authors include Harold R. Collard, Mark G. Jones, Ganesh Raghu, Athol U. Wells, Susanne Stowasser, Vincent Cottin, Moisés Selman, Giacomo Sgalla, Fernando J. Martínez and Martin Kolb and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Luca Richeldi

332 papers receiving 17.9k citations

Hit Papers

Idiopathic pulmonary fibrosis 2011 2026 2016 2021 2017 2019 2017 2011 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Idiopathic pulmonary fibrosis
    2017 1.4k citations Luca Richeldi, Mark G. Jones et al. profile →
  2. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    2019 1.3k citations Kevin R. Flaherty, Athol U. Wells et al. profile →
  3. Idiopathic pulmonary fibrosis
    2017 903 citations Fernando J. Martínez, Ganesh Raghu et al. profile →
  4. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
    2011 811 citations Luca Richeldi, Kevin M. Brown et al. profile →
  5. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children
    2016 656 citations Luca Richeldi et al. profile →
  6. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
    2017 655 citations Kevin M. Brown, Yoshikazu Inoue et al. profile →
  7. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
    2015 655 citations Kevin M. Brown, Tamera J. Corte et al. European Respiratory Journal profile →
  8. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children
    2017 476 citations Luca Richeldi et al. profile →
  9. Idiopathic pulmonary fibrosis: pathogenesis and management
    2018 413 citations Giacomo Sgalla, Bruno Iovene et al. profile →
  10. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
    2016 330 citations Luca Richeldi, Vincent Cottin et al. Respiratory Medicine profile →
  11. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
    2020 208 citations Michael Kreuter, Fernando J. Martínez et al. profile →
  12. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress
    2020 190 citations Ganesh Raghu, Michael Berk et al. Current Neuropharmacology profile →
  13. Idiopathic pulmonary fibrosis: state of the art for 2023
    2023 175 citations Anna J. Podolanczuk, Luca Richeldi et al. European Respiratory Journal profile →
  14. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
    2022 139 citations Luca Richeldi, Arata Azuma et al. profile →
  15. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
    2022 130 citations Alessia Comes, Luca Richeldi et al. profile →
  16. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
    2025 28 citations Luca Richeldi, Arata Azuma et al. profile →
  17. Nerandomilast in Patients with Progressive Pulmonary Fibrosis
    2025 19 citations Toby M. Maher, Shervin Assassi et al. profile →

Peers

Luca Richeldi
Comparison fields: 5 of 162
  • Pulmonary and Respiratory Medicine 13.1k
  • Physiology 4.8k
  • Epidemiology 3.9k
  • Infectious Diseases 2.8k
  • Surgery 2.5k
Replace Dominique Valeyre with:
Dominique Valeyre France
Ulrich Costabel Germany
Vincent Cottin France
James E. Loyd United States
Ganesh Raghu United States
Athol U. Wells United Kingdom
Andrew H. Limper United States
Henry D. Tazelaar United States
Marc A. Judson United States
P. Cacoub France
Dominique Valeyre France View profile →
Citations per field, relative to Luca Richeldi
Luca Richeldi · 1×
Citations per year, relative to Luca Richeldi
Luca Richeldi · 1×

Countries citing papers authored by Luca Richeldi

Since Specialization
Citations

This map shows the geographic impact of Luca Richeldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Richeldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Richeldi more than expected).

Fields of papers citing papers by Luca Richeldi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Richeldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Richeldi. The network helps show where Luca Richeldi may publish in the future.

Co-authorship network of co-authors of Luca Richeldi

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Richeldi. A scholar is included among the top collaborators of Luca Richeldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Richeldi. Luca Richeldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis
2025 ·CHEST Journal ·(unknown), Toby M. Maher, Wim Wuyts, Claudia Valenzuela, Michael R. Hamblin, Sinae Kim, (unknown), (unknown), Luca Richeldi
1
2
Ultrathin bronchoscopy-guided small airway biopsy for diagnosing sarcoidosis: A prospective study
2024 ·Pulmonology ·Rocco Trisolini, Giovanni Sotgiu, (unknown), Giuliana Pasciuto, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mariangela Valentina Puci, Luca Richeldi
0
3
Promising advances in treatments for the management of idiopathic pulmonary fibrosis
2024 ·Expert Opinion on Pharmacotherapy ·Carmelo Sofia, Alessia Comes, Giacomo Sgalla, Luca Richeldi
6
4
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
2024 ·American Journal of Respiratory and Critical Care Medicine ·Jürgen Behr, Margaret L. Salisbury, Simon Walsh, Anna J. Podolanczuk, Lida P. Hariri, Gary M. Hunninghake, Martin Kolb, Christopher J. Ryerson, Vincent Cottin, Mary Beth Beasley, Tamera J. Corte, Allan R. Glanville, Ayodeji Adegunsoye, Cory M. Hogaboam, Wim Wuyts, Imre Noth, Justin M. Oldham, Luca Richeldi, Ganesh Raghu, Athol U. Wells
11
5
POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
2023 ·Annals of the Rheumatic Diseases ·Toby M. Maher, (unknown), Arata Azuma, Vincent Cottin, (unknown), Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies Wijsenbeek, Carl Coeck, (unknown), Daniel Wachtlin, Fernando J. Martínez
0
6
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
2023 ·BMJ Open Respiratory Research ·Toby M. Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna‐Maria Hoffmann‐Vold, Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies Wijsenbeek, Carl Coeck, Christina Schlecker, Florian Voß, Daniel Wachtlin, Fernando J. Martínez
16
7
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
2021 ·Therapeutic Advances in Respiratory Disease ·Giorgio Walter Canonica, Pierluigi Paggiaro, Francesco Blasi, Antonino Musarra, Luca Richeldi, Andrea Rossi, Alberto Papi
10
8
COVID-related fibrosis: insights into potential drug targets
2021 ·Expert Opinion on Investigational Drugs ·Giacomo Sgalla, Alessia Comes, (unknown), Luca Richeldi
7
9
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
2021 ·European Respiratory Journal ·Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Luca Richeldi, Simon Walsh, Martin Kolb, Dirk Koschel, Teng Moua, Susanne Stowasser, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Kevin K. Brown
65
10
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress breakdown →
2020 ·Current Neuropharmacology ·Ganesh Raghu, Michael Berk, Peter A. Campochiaro, Hartmut Jaeschke, Giancarlo Marenzi, Luca Richeldi, Fuqiang Wen, Ferdinando Nicoletti, Peter Calverley
190
11
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement
2020 ·Diagnostics ·Enrico De Lorenzis, Silvia Laura Bosello, Francesco Varone, Giacomo Sgalla, Lucio Calandriello, G. Natalello, Bruno Iovene, Giuseppe Cicchetti, Laura Gigante, Lucrezia Verardi, Elisa Gremese, Luca Richeldi, Anna Rita Larici
19
12
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?
2020 ·ERJ Open Research ·Christopher J. Brereton, T Wallis, Michelle Casey, (unknown), (unknown), D. Richard Laws, (unknown), (unknown), (unknown), (unknown), A Grove, (unknown), Luca Richeldi, Katherine Ma O’Reilly, Sophie Fletcher, Mark G. Jones
18
13
Telemedicine-enabled Accelerated Discharge of Patients Hospitalized with COVID-19 to Isolation in Repurposed Hotel Rooms
2020 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Ajit Lalvani, Luca Richeldi
16
14
Contemporary Concise Review 2018: Interstitial lung disease
2019 ·Respirology ·(unknown), Mark G. Jones, Luca Richeldi
7
15
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients
2019 ·Multiple Sclerosis and Related Disorders ·Assunta Bianco, (unknown), Anna Rita Larici, Matteo Lucchini, Viviana Nociti, Francesco Antonio Losavio, Chiara De Fino, Giuseppe Cicchetti, Daniele Coraci, Luca Richeldi, Massimiliano Mirabella
6
16
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies
2019 ·American Journal of Respiratory and Critical Care Medicine ·Robert J. Kaner, Ednan K. Bajwa, Moustapha El-Amine, Eduard Gorina, Renu Gupta, (unknown), Tracy Luckhardt, Majd Mouded, (unknown), Luca Richeldi, John L. Stauffer, Ahmet Tütüncü, Fernando J. Martínez
7
17
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
2018 ·Respiratory Medicine ·Kevin M. Brown, Kevin R. Flaherty, Vincent Cottin, Ganesh Raghu, Yoshikazu Inoue, Arata Azuma, John T. Huggins, Luca Richeldi, Susanne Stowasser, Wibke Stansen, Rozsa Schlenker‐Herceg, Toby M. Maher, Athol U. Wells
26
18
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
2018 ·ERJ Open Research ·Sophie Fletcher, Mark G. Jones, Elisabetta Renzoni, Helen Parfrey, Rachel K. Hoyles, (unknown), Maria Kokosi, (unknown), Chris Warburton, (unknown), Muhunthan Thillai, (unknown), Toby M. Maher, Christopher J. Brereton, Felix Chua, Athol U. Wells, Luca Richeldi, Lisa Spencer
26
19
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
2015 ·BMC Medicine ·Luca Richeldi, Adalberto Sperb Rubin, С. Н. Авдеев, Zarir Udwadia, Zuo Jun Xu
32
20
T Cell–Based Tracking of Multidrug Resistant Tuberculosis Infection after Brief Exposure
2004 ·American Journal of Respiratory and Critical Care Medicine ·Luca Richeldi, Katie Ewer, Monica Losi, Barbara Maria Bergamini, Pietro Roversi, Jonathan J Deeks, Leonardo M. Fabbri, Ajit Lalvani
115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dominique Valeyre Breakdown of academic impact, for papers by Ulrich Costabel Breakdown of academic impact, for papers by Vincent Cottin Breakdown of academic impact, for papers by James E. Loyd Breakdown of academic impact, for papers by Ganesh Raghu Breakdown of academic impact, for papers by Athol U. Wells Breakdown of academic impact, for papers by Andrew H. Limper Breakdown of academic impact, for papers by Henry D. Tazelaar Breakdown of academic impact, for papers by Marc A. Judson Breakdown of academic impact, for papers by P. Cacoub
Rankless by CCL
2026